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Abstract
Background: Due to its rising prevalence type 2 diabetes plays an important role concerning
population health in Austria and other western countries. In various studies deficiencies in the care
of diabetic patients have been revealed. These deficiencies may be overcome by disease-
management-programmes (DMPs), but international experience shows that the effectiveness of
DMPs is inconsistent. In particular large programmes designed by state-affiliated public health
insurances have not been evaluated in randomized controlled trials (RCTs). We are therefore
conducting a large scale RCT of the Austrian DMP for type 2 diabetic patients in the province of
Salzburg to evaluate the programme regarding its effects on metabolic control, guideline adherent
care and the quality of life of diabetic patients.
Methods/Design: The study is open for participation to all GPs and internists in the province of
Salzburg. Physicians are randomized before recruitment of patients with the districts of Salzburg as
clusters of randomisation. A total of over 1200 patients with type 2 diabetes will then be recruited.
In the intervention group the DMP is applied for one year. Controls receive usual care. Endpoints
are a decrease in HbA1c in the intervention group > 0,5% compared to controls, a higher
percentage of patients with required diagnostic measures according to guidelines, improved
cardiovascular risk profile and higher quality of life scores within one year.
Current status of the study: 98 Physicians agreed to participate in the study. 96 of them
recruited 1494 patients, 654 in the intervention and 840 in the control group.
Trail Registration: This trial has been registered with Current Controlled Trials Ltd.
(ISRCTN27414162).
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Background
The prevalence of type 2 diabetes is rising worldwide [1].
In Austria about 3,5 – 5% of the population are affected
and it has been shown that diabetes care is insufficient [2].
The socioeconomic impact of the disease is alarming and
it is necessary to improve its prevention and control. Effec-
tive screening for early detection and structured care
according to current guidelines are the most promising
strategies to avoid diabetic complications. One of the con-
cepts to assure optimized care is the design of disease
management programmes comprising physician training
in guideline-adherent therapy and patient education as
well as reminders and continuous feedback. Unfortu-
nately disease management programmes don't seem to
guarantee optimum care. As has been shown in Germany,
a nation-wide implementation of DMPs by mandatory
public health insurances may rather lead to increasing
bureaucracy than to an improvement in care. Therefore
the programmes have been criticized widely [3]. Evalua-
tion studies have not been carried out as randomized con-
trolled trials, and have been restricted to small samples of
highly motivated physicians. Thus, results so far are not
sufficient to support a general implementation [4]. Rand-
omized controlled trials that have been performed in var-
ious countries have never evaluated large programmes of
state-affiliated public health insurances, and showed only
limited success, especially regarding clinically relevant
endpoints. DMPs may – depending on the programme –
improve surrogate parameters like HbA1c, but didn't
show any effect on cardiovascular morbidity and mortal-
ity after six years of observation [5].
In a systematic review the authors conclude that the
majority of DMPs lead to an improvement in metabolic
control, but this appears to be largely dependent on the
individual programme and its particular design [6]. Thus,
physician training leads to an improvement of metabolic
control only in 38% of the studies included in the review,
and to increased guideline adherence in 50% of the stud-
ies. Patient education was shown to be effective in 44% of
the studies.
Another systematic review published in 2004 came up
with similar results. Only in 24 out of 66 randomized con-
trolled trials on the effectiveness of DMPs a significant
improvement in patient care and metabolic control was
demonstrated [7].
One systematic review achieved slightly better results but
included non-controlled studies as well as studies per-
formed in HMOs (Health Maintenance Organisations)
and Community Clinics. The results can hardly be trans-
ferred to single GP surgeries [8].
The effectiveness of patient education has been explicitly
evaluated in a Cochrane-Review. The authors conclude
with caution that patient education in groups may tend to
improve metabolic control. 10 out of the 11 studies
included in the review are considered to have serious
methodological deficits [9]. Among these the study of Pie-
ber et al. is also criticised. The development of the DMP of
the Austrian Public Health Insurance has been partly
based on this study. It is characterised by non-randomized
controls, a short observation period and a small number
of highly motivated surgeries [10].
All these reviews show clearly that there are large discrep-
ancies and variations from study to study regarding the
effectiveness of a DMP. One of the explanations may be
that there are important differences in the design, making
each DMP a unique intervention in a unique setting that
may not be comparable to other DMPs even though the
basic elements (physician training, patient education,
reminders etc.) remain the same. We therefore believe that
a newly designed DMP must be evaluated in its particular
setting before general implementation can be recom-
mended. This is especially true for large public pro-
grammes that not only impose additional work on the
surgeries involved but also cause tremendous cost to the
health care system.
The prerequisites of summative evaluation of public
health interventions have been described in the context of
international expertise and comprise the performance of a
randomized controlled trial prior or at least parallel to
their general implementation [11]. In several instances,
i.e. in the implementation process of DMPs by public
health insurances in Germany this rigorous evaluation has
not been performed, leading to persistent criticism and
scepticism regarding the effectiveness of these pro-
grammes [12]. Now a summative and controlled evalua-
tion is not possible anymore because the programmes
have been implemented all over the country.
In Austria we are currently facing the plan of a nationwide
implementation of a DMP for type 2 diabetes. To avoid
the lack of a summative evaluation as presently missing in
Germany we suggested to the public health insurance and
health authorities of Salzburg to implement the DMP
starting with a RCT.
Objectives of the study
The study focuses on the following aspects of effectiveness
of the DMP for type 2 diabetic patients (called „Therapie
aktiv“) designed by the Austrian public health insurance:
￿ Does metabolic control improve in type 2 diabetics par-
ticipating in the DMP „Therapie aktiv“ compared to con-
trols receiving usual care after one year of observation?Trials 2008, 9:38 http://www.trialsjournal.com/content/9/1/38
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￿ Is guideline-adherent care regarding metabolic control
and early detection of diabetic complications improved in
DMP-patients compared to controls receiving usual care?
￿ Is guideline-adherent therapy of type 2 diabetes and its
complications improved in DMP-patients compared to
controls receiving usual care?
￿ Is guideline-adherent therapy of cardiovascular risk fac-
tors improved in DMP-patients compared to controls
receiving usual care?
The primary objective of the study is to show that the Aus-
trian DMP for diabetes mellitus type 2 improves meta-
bolic control of patients with diabetes. This improvement
must exceed a decrease of HbA1c of 0.5% between the
beginning and the end of the study in the intervention
group compared to the controls (see endpoints).
Secondary objectives are to demonstrate that the Austrian
DMP leads to an improvement of guideline adherent
treatment and an increased frequency of the recom-
mended preventive examinations regarding diabetic com-
plications (i.e. frequency of eye examinations, foot
examinations, testing for microalbuminuria, serum creat-
inine and plasma lipids). Another secondary objective of
the study is the calculation of the effect of the DMP on
economic issues (i.e. prospective hospital admissions and
economic burden due to diabetic complications).
Methods/Design
Study Design
The study is performed as a cluster-randomized controlled
trial of a complex intervention with an observation time
of one year. Randomization-clusters are the districts of the
province of Salzburg because randomization is neither
feasible at the level of the patient nor at the level of the
GP. Randomization at the level of the patient leads to the
problem that a single GP would have to treat some
patients according to usual care and others according to
the DMP which is hardly possible because of "contamina-
tion" effects. Also, randomization at the level of the GP
appears not to be advisable, because this would lead to
contamination effects especially in rural areas, where
neighbouring GPs have overlapping patient groups.
Patients knowing one another and belonging one to the
intervention and the other to the control group, may even
switch their physician.
Setting and Study Population
The study takes place in the province of Salzburg, consist-
ing of Salzburg city with about 150.000 inhabitants and
five districts (suburban and rural areas including a few
larger villages with a total of about 350.000 inhabitants.
The prevalence of type 2 diabetes in this population is
estimated to be about 2.5 to 3%.
Recruitment and Randomization
Recruitment of the surgeries
Participation in the study is offered to all physicians who
are eligible to participate in the DMP, i.e. all GPs and spe-
cialists in internal medicine with their own surgery and a
contract with the public health insurance (252 GPs and 23
specialists in internal medicine). We inform all of the 275
physicians in writing about the study and its objectives
and ask them to respond by letter or fax to declare their
willingness to participate. Furthermore, we offer addi-
tional information by phone. All physicians are informed
explicitly that the study will be a randomized controlled
trial, and that randomization will only take place after a
commitment to participate has been made. Therefore, at
the time of signing up the physicians do not know which
group – intervention or control – they will belong to.
Randomisation
Randomisation takes place at the level of the districts after
completion of physician recruitment. The city of Salzburg
as the only urban region of the province is divided into
two study districts (one being to the right, the other to the
left of the Salzach, the river that divides the city in nearly
two halves). To assure even distribution of the districts
regarding population characteristics and size the districts
are randomized as matched pairs. Salzburg city to the
right of the Salzach is matched with the city left of the
Salzach, the district Pongau is matched with Pinzgau and
Lungau (mostly mountainous regions with remote vil-
lages), and the district Flachgau is matched with Tennen-
gau (both adjacent to Salzburg city with partially
suburban and partially agricultural regions, more densely
populated than the mountain districts). The randomiza-
tion process is performed under the supervision of a com-
mittee comprising representatives of Paracelsus
University, the Austrian public health insurance, the
Working-group for Preventive Medicine, Salzburg (AVOS)
and the healthcare department of the government of the
province.
Recruitment of patients
All patients (> 18 years) with type 2 diabetes that fulfil the
WHO/ADA-criteria for diabetes diagnosis are eligible to
participate in the study. The physicians are encouraged to
continuously recruit all patients with type 2 diabetes that
enter the surgery during the recruitment period (from July
1st to October 31st of 2007). All patients willing to partici-
pate are included in the study after informed consent
according to the declaration of Helsinki.Trials 2008, 9:38 http://www.trialsjournal.com/content/9/1/38
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Exclusion criteria are dementia/psychiatric illness with
inability to participate or to give informed consent, or
known major consuming illness (i.e. advanced cancer).
Intervention
In the intervention group the complex intervention of the
DMP for type 2 diabetes as designed by the Austrian pub-
lic health insurance ("Therapie aktiv") is applied, consist-
ing of:
￿ a 10-hour training course for all physicians of the inter-
vention group as designed by the Austrian Diabetes Asso-
ciation (ÖDG), the Austrian Medical College
(Ärztekammer), and the Austrian Society for General Prac-
tice (ÖGAM). Physicians are trained by experienced GPs
and specialists from the diabetes unit of the Medical
Department I of the University Hospital Salzburg, and
from the Institute of General Practice, Family Medicine
and Prevention, both of Paracelsus Medical University
(PMU)
￿ 9 hours of patient-education in 4 modules with a group
size of 3 to 12 patients. Patient education is organized by
the Workgroup for preventive medicine Salzburg (AVOS)
according to the curriculum of the „Düsseldorfer Modell“
[13] and performed by especially trained physicians in
their surgeries or in hospital out-patient clinics. The mod-
ules have been offered all over the province long before
the implementation of the DMP (i.e. the study) but have
not been used widely enough.
￿ documentation in a DMP-form at the beginning and at
the end of the study year.
￿ structured interdisciplinary care as prescribed in the
DMP according to the guidelines of the Austrian Diabetes
Association (ÖDG).
￿ patient and physician reminders every three months
sent out by the public health insurance to assure adher-
ence to the schedule of prescribed diagnostic and thera-
peutic measures.
￿ agreement on therapeutic goals in a shared decision-
making process of patient and physician.
Control
In the control group the physicians perform the standard
care as prescribed by current guidelines for the manage-
ment of type 2 diabetes. Continuous medical education
and patient education are allowed at the discretion of the
particular physician or patient.
Documentation and Monitoring
Baseline-Examination
At inclusion the following parameters are examined and
recorded:
• Laboratory: Fasting and postprandial blood glucose,
HbA1c, cholesterol, triglycerides, HDL-cholesterol
￿ Anthropometric measurements: Height and body
weight, systolic and diastolic blood pressure
￿ Case Report Form: In the intervention group the DMP
documentation form is used. To avoid bias, a simplified
case report form is used in the control group. Some
parameters (i.e. known diabetic complications) will be
registered at the end of the study, see below).
Final examination
After one year baseline data will be recorded once again.
In an additional case report form diabetic complications
(present already at the beginning, and those that arose
during the year), cardiovascular events, hospitalization,
hypoglycaemias, diagnostic and therapeutic measures as
well as therapeutic goals will be recorded (i.e. ophthalmo-
logical, neurological, podological, and nephrological
examinations). Quality of life will be evaluated with the
German version of the EQ-5 which has been used in the
UKPDS (Version EQ5-D) [14].
Endpoints
The primary endpoint of the trial will be the change in
HbA1c from baseline to 12 months (final examination).
Secondary outcomes will include a reduction in the
amount of time spent in a hospital during the year of the
study, a higher percentage of patients with guideline
adherent diagnostic and therapeutic measures (i.e. eye
examination, foot examination frequency) during the
study, as well as improved control of cardiovascular risk
and a higher EQ5-D-score in the intervention group at the
end of the study.
The differences between the intervention group and the
control group regarding primary and secondary endpoints
will allow an estimate of the impact of the DMP on health
economics.
Data management and calculation of sample size
All data are recorded in the surgeries of the participating
physicians and then transferred to the Institute of General
Practice, Family Medicine and Prevention of the PMU for
further processing and evaluation.
Sample size was calculated using the primary endpoint,
i.e. the change in HbA1c from baseline to final examina-
tion at 12 months. Using an estimate of standard devia-Trials 2008, 9:38 http://www.trialsjournal.com/content/9/1/38
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tion for HbA1c change of 2%, a total of 504 patients (252
per arm) would be required to detect a difference of
HbA1c of 0.5% (effect size, 0.25) with a power of 1-β =
80% using a two-sided two-sample t-test at a 0.05 signifi-
cance level. Assuming an intracluster correlation coeffi-
cient of 0.05 and an average cluster size of 20, we
estimated a design effect of D = 1 + (20-1) × 0.05 = 1.95.
Thus, to have adequate power, the sample size had to be
increased to 984 patients (492 per arm). Assuming a drop-
out-rate of 20%, the sample size was adjusted to 615
patients per arm, or a total of 1230 patients.
Statistical Analysis
All data will be analyzed on an intention to treat basis.
The primary efficacy analysis will be to compare the
change in the HbA1c from baseline to 12 months in the
intervention and control groups. For all primary and sec-
ondary outcome variables, we will analyze differences
between groups by using mixed models in SPSS 13.5 to
allow for clustering. We will add all relevant baseline char-
acteristics at patient level (age, sex, educational level, car-
diovascular risk, clinical vascular disease, medication for
primary and secondary prevention) as well as at cluster
level if applicable as covariates to the models. Results of
two-sided tests between study arms will be regarded sig-
nificant at p < 0.05.
Ethical issues and trial registration
This trial has been approved by the ethics committee of
Salzburg, Austria, and has been registered with Current
Controlled Trials Ltd. (ISRCTN27414162).
Current status of the study
Recruitment of the surgeries took place from April 18th to
June 5th 2007. 98 Physicians declared themselves willing
to participate in the study (88 GPs and 10 specialists in
internal medicine) yielding a participation rate of 35.6%
of all physicians eligible. Randomization took place on
June 5th 2007. Salzburg city to the left of the Salzach river
and the districts Pinzgau, Lungau and Tennengau were
allocated to the intervention group (48 physicians), Salz-
burg city to the right of the Salzach river and the districts
Flachgau and Pongau form the control group (50 physi-
cians). The physicians of the intervention group received
their DMP-training-courses in June and July of 2007.
Recruitment of patients took place from July 1st to Octo-
ber 31st  2007. Two surgeries dropped out and didn't
recruit any patients. 1494 patients entered the study (654
in the intervention group and 840 in the control group).
Baseline data are currently being processed.
Discussion
Our study not only aims at a thorough summative evalu-
ation of the Austrian DMP for type 2 diabetes, it also rep-
resents the first RCT of a DMP developed and
implemented by a state-affiliated public health insurance.
Such a study was proposed in Germany before the imple-
mentation of DMPs but for political reasons has never
been carried out [3,12]. The current evaluation of the Aus-
trian DMP avoids these deficiencies and will yield the nec-
essary data to estimate effectiveness and economic effects
of the programme. A major drawback of course is the
study length. A study period of only one year will not be
sufficient to show any effects on clinically relevant end-
points such as cardiovascular events, diabetic complica-
tions or mortality. This drawback, however, is
encountered in many studies of therapeutic interventions
which only investigate the effect on surrogate parameters
like HbA1c. The UKPDS has shown the HbA1c to be a rel-
evant surrogate for clinical endpoints in the long run
[15,16]. Thus an improvement of HbA1c attributable to a
DMP may be taken as the best available evidence for a
clinically relevant effect. We therefore chose the HbA1c as
the primary endpoint of our trial. HbA1c-associated
effects on microvascular disease and health economics
may be estimated from the results of the UKPDS. In a
metaanalysis of the relationship between HbA1c and car-
diovascular outcome a 1.18 fold increase of risk has been
shown for a 1-percentage point increase of HbA1c [17].
Using this risk prediction in the comparison between
intervention and control group the possible benefit
regarding morbidity, mortality and economic factors per-
taining to macrovascular disease may be cautiously esti-
mated.
Another drawback of our RCT is the possibility of bias due
to the cluster randomization and the lack of blinding. Of
course, blinding of a complex intervention is not possible.
Thus physicians in the intervention group may recruit dif-
ferent patients than those in the control group. Adjust-
ments for these differences using multivariate testing will
help to avoid and overcome this bias. As mentioned
above, we chose randomization at the level of the district
to avoid contamination. Nonetheless we prefer to per-
form the evaluation at the patient level because the bene-
fit regarding clinical outcome is most important to the
individual patient. The drawback of this approach is that
cluster effects may be underestimated. Specific analysis of
these effects and inclusion in the evaluation models will
help to avoid this bias.
Another possible weakness may be the sample of partici-
pating physicians. Although the overall participation rate
was quite high, the sample may not be representative for
all GPs and internists in the country. It rather represents a
subgroup more open to innovation and highly motivated
to improve patient care. Nevertheless we feel that the sam-
ple may be quite representative for the physicians that will
finally apply the DMP in everyday practice.Trials 2008, 9:38 http://www.trialsjournal.com/content/9/1/38
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Conclusion
If the DMP does not work in the study it will surely not
work with the physicians that are less motivated than
those under investigation. We therefore believe this trial
to be a landmark in the evaluation of DMPs developed
and implemented by public health insurance. Revealing
positive results will not only allow an estimate of the
DMP's impact on health economics, but will also lead to
an increased acceptance of the DMP among GPs and thus
improve diabetes care in the population. This may have a
long-term effect on healthcare and health economics in
Austria and in countries with similar public programmes.
Furthermore the present programme can be optimized
using the results of the RCT.
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